Hoth Therapeutics Inc (HOTH)

$0.66 0.00 (-0.03%)
Market Cap 12.63M
Revenue (ttm) 0.00
Net Income (ttm) -12.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 224,000
Avg Vol 3,091,712
Day's Range N/A - N/A
Shares Out 19.13M
Stochastic %K 9%
Beta 0.57
Analysts Strong Sell
Price Target $4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 239 7459
Address:
720 Monroe Street, Suite E514, Hoboken, United States
SuperGreenToday
SuperGreenToday May. 13 at 3:50 AM
$HOTH
0 · Reply
Tino321
Tino321 May. 13 at 12:56 AM
$HOTH this will be my worst or best investment, so far it’s been horrible lol
0 · Reply
Kri81
Kri81 May. 12 at 7:42 PM
$HOTH Nano rockets
0 · Reply
Kri81
Kri81 May. 12 at 5:40 PM
$HOTH Fly Me to the Moon
1 · Reply
companyofone
companyofone May. 11 at 11:20 PM
$HOTH maybe they will sell the medical for billions, stock goes to $50 we make 1000x and now they have the money to nanobot the world with instant vaxes and charge in btc?? Hmmm 🤔 not to far out there. Anyone else have thoughts
1 · Reply
thefly2
thefly2 May. 11 at 9:57 AM
$MNTS have one to keep an eye on. They filed an 8k and have not done a PR on it yet, I’m assuming when they do it will be a fast move dice its outstanding share count is small. $HOTH
2 · Reply
thefly2
thefly2 May. 8 at 5:42 PM
$HOTH We know there will be more PR’s coming with the recent 8k
0 · Reply
Johnnyb1973
Johnnyb1973 May. 8 at 1:07 PM
$HOTH 🤜💎🤛
0 · Reply
Bearbull_Baggins
Bearbull_Baggins May. 8 at 10:15 AM
$HOTH Ok....wut? A space subsidiary? Uhhhh....k. Bullish? I think, maybe, i dunno. Trying to bait algos into pumping Hoth over a buck with some buzzwords?
0 · Reply
Tino321
Tino321 May. 8 at 8:14 AM
$HOTH down 12K 😂 this stock mannnnn
0 · Reply
Latest News on HOTH
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

May 5, 2026, 4:17 PM EDT - 7 days ago

Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Hoth Therapeutics reports results from HT-VA study

2026-04-14T11:15:01.000Z - 4 weeks ago

Hoth Therapeutics reports results from HT-VA study

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Apr 14, 2026, 7:00 AM EDT - 4 weeks ago

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Hoth Therapeutics reports positive HT-VA CRADA data

2026-04-13T21:31:04.000Z - 4 weeks ago

Hoth Therapeutics reports positive HT-VA CRADA data

Hoth Therapeutics up 52% at $0.78 per share after HT-VA data

2026-04-13T21:30:13.000Z - 4 weeks ago

Hoth Therapeutics up 52% at $0.78 per share after HT-VA data

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Apr 2, 2026, 4:05 PM EDT - 5 weeks ago

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Hoth Therapeutics announces $2M registered direct offering

2026-04-01T18:00:34.000Z - 5 weeks ago

Hoth Therapeutics announces $2M registered direct offering

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Apr 1, 2026, 1:52 PM EDT - 5 weeks ago

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Hoth Therapeutics reports results from ongoing HT-001 program

2026-04-01T12:17:13.000Z - 6 weeks ago

Hoth Therapeutics reports results from ongoing HT-001 program

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Apr 1, 2026, 8:14 AM EDT - 6 weeks ago

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Hoth Therapeutics announces issuance of Chinese patent

2026-03-31T12:18:35.000Z - 6 weeks ago

Hoth Therapeutics announces issuance of Chinese patent

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Mar 31, 2026, 8:07 AM EDT - 6 weeks ago

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Mar 26, 2026, 8:30 AM EDT - 6 weeks ago

Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity

2026-03-24T12:27:10.000Z - 7 weeks ago

Hoth Therapeutics’ HT-001 shows positive PK, safety and clinical activity

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Mar 24, 2026, 8:13 AM EDT - 7 weeks ago

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Hoth Therapeutics’ HT-VA shows cholesterol level restoration

2026-03-10T12:21:41.000Z - 2 months ago

Hoth Therapeutics’ HT-VA shows cholesterol level restoration

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Mar 10, 2026, 8:13 AM EDT - 2 months ago

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Mar 4, 2026, 8:31 AM EST - 2 months ago

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Hoth Therapeutics announces expansion of CLEER-001 Phase 2a clinical trial

2026-02-24T21:28:07.000Z - 2 months ago

Hoth Therapeutics announces expansion of CLEER-001 Phase 2a clinical trial

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Feb 24, 2026, 4:15 PM EST - 2 months ago

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Hoth Therapeutics receives U.S. notice of allowance for Exon-skipping therapy

2026-02-12T13:42:04.000Z - 3 months ago

Hoth Therapeutics receives U.S. notice of allowance for Exon-skipping therapy

Hoth Therapeutics’ HT-VA GDNF shows superior efficacy in obesity

2026-02-10T13:35:50.000Z - 3 months ago

Hoth Therapeutics’ HT-VA GDNF shows superior efficacy in obesity

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Feb 10, 2026, 8:30 AM EST - 3 months ago

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Hoth Therapeutics confirms it holds no cryptocurrency assets

2026-02-05T13:12:10.000Z - 3 months ago

Hoth Therapeutics confirms it holds no cryptocurrency assets

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Feb 5, 2026, 8:03 AM EST - 3 months ago

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Hoth Therapeutics’ HT-001 shows 100% response in EFGR-treated cancer patients

2026-01-22T13:27:33.000Z - 3 months ago

Hoth Therapeutics’ HT-001 shows 100% response in EFGR-treated cancer patients

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Jan 22, 2026, 8:13 AM EST - 3 months ago

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics receives approval for HT-KIT cancer program patent in China

2026-01-21T13:21:25.000Z - 3 months ago

Hoth Therapeutics receives approval for HT-KIT cancer program patent in China

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Jan 21, 2026, 8:13 AM EST - 3 months ago

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Jan 15, 2026, 8:17 AM EST - 4 months ago

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics expands oncology pipeline with dual patent filings

2026-01-02T13:25:06.000Z - 4 months ago

Hoth Therapeutics expands oncology pipeline with dual patent filings

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Jan 2, 2026, 8:13 AM EST - 4 months ago

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Dec 3, 2025, 2:00 PM EST - 5 months ago

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Dec 1, 2025, 8:03 AM EST - 5 months ago

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Hoth Therapeutics accepted into Nvidia Connect Program

2025-11-20T13:21:16.000Z - 6 months ago

Hoth Therapeutics accepted into Nvidia Connect Program

NVDA

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Nov 20, 2025, 8:13 AM EST - 6 months ago

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Hoth Therapeutics files $50M mixed securities shelf

2025-11-17T11:05:18.000Z - 6 months ago

Hoth Therapeutics files $50M mixed securities shelf

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 27, 2025, 7:49 AM EDT - 7 months ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics’ HT-KIT granted FDA Orphan Drug Designation

2025-10-21T12:30:33.000Z - 7 months ago

Hoth Therapeutics’ HT-KIT granted FDA Orphan Drug Designation

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 21, 2025, 8:23 AM EDT - 7 months ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics selects Nvidia AI enterprise platform

2025-10-08T12:05:21.000Z - 7 months ago

Hoth Therapeutics selects Nvidia AI enterprise platform

NVDA

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 8, 2025, 8:02 AM EDT - 7 months ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Oct 7, 2025, 7:57 AM EDT - 7 months ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 24, 2025, 8:13 AM EDT - 8 months ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 16, 2025, 8:14 AM EDT - 8 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 10, 2025, 8:29 AM EDT - 8 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 4, 2025, 8:16 AM EDT - 8 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Sep 2, 2025, 8:16 AM EDT - 9 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 29, 2025, 7:58 AM EDT - 10 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jul 22, 2025, 8:19 AM EDT - 10 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 11 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 24, 2025, 10:36 AM EDT - 11 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 23, 2025, 8:03 AM EDT - 11 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 1:34 PM EDT - 11 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 18, 2025, 8:22 AM EDT - 11 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 12, 2025, 9:17 AM EDT - 11 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 11, 2025, 8:28 AM EDT - 1 year ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 1 year ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

May 12, 2025, 7:30 AM EDT - 1 year ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 17, 2025, 8:01 AM EDT - 1 year ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 15, 2025, 8:19 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Apr 2, 2025, 7:58 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 31, 2025, 4:45 PM EDT - 1 year ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 26, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 18, 2025, 8:06 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 10, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 5, 2025, 1:40 PM EST - 1 year ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

SuperGreenToday
SuperGreenToday May. 13 at 3:50 AM
$HOTH
0 · Reply
Tino321
Tino321 May. 13 at 12:56 AM
$HOTH this will be my worst or best investment, so far it’s been horrible lol
0 · Reply
Kri81
Kri81 May. 12 at 7:42 PM
$HOTH Nano rockets
0 · Reply
Kri81
Kri81 May. 12 at 5:40 PM
$HOTH Fly Me to the Moon
1 · Reply
companyofone
companyofone May. 11 at 11:20 PM
$HOTH maybe they will sell the medical for billions, stock goes to $50 we make 1000x and now they have the money to nanobot the world with instant vaxes and charge in btc?? Hmmm 🤔 not to far out there. Anyone else have thoughts
1 · Reply
thefly2
thefly2 May. 11 at 9:57 AM
$MNTS have one to keep an eye on. They filed an 8k and have not done a PR on it yet, I’m assuming when they do it will be a fast move dice its outstanding share count is small. $HOTH
2 · Reply
thefly2
thefly2 May. 8 at 5:42 PM
$HOTH We know there will be more PR’s coming with the recent 8k
0 · Reply
Johnnyb1973
Johnnyb1973 May. 8 at 1:07 PM
$HOTH 🤜💎🤛
0 · Reply
Bearbull_Baggins
Bearbull_Baggins May. 8 at 10:15 AM
$HOTH Ok....wut? A space subsidiary? Uhhhh....k. Bullish? I think, maybe, i dunno. Trying to bait algos into pumping Hoth over a buck with some buzzwords?
0 · Reply
Tino321
Tino321 May. 8 at 8:14 AM
$HOTH down 12K 😂 this stock mannnnn
0 · Reply
Kri81
Kri81 May. 7 at 9:36 PM
$HOTH Are we on the way to the moon now?
0 · Reply
Kri81
Kri81 May. 7 at 9:35 PM
$HOTH Whats happening??????
0 · Reply
thefly2
thefly2 May. 7 at 2:22 PM
$HOTH Here you go
1 · Reply
thefly2
thefly2 May. 7 at 2:12 PM
$HOTH Joining the rocket space now???
0 · Reply
thefly2
thefly2 May. 7 at 2:06 PM
$HOTH $RMSG $GLE check this out
0 · Reply
BigFish12p
BigFish12p May. 7 at 11:34 AM
$HOTH anyone see this 8k yesterday. Something is up
0 · Reply
thefly2
thefly2 May. 6 at 5:18 PM
$HOTH Should have got more attention on the good news
0 · Reply
thefly2
thefly2 May. 5 at 10:21 PM
$HOTH
0 · Reply
thefly2
thefly2 May. 5 at 10:18 PM
$HOTH $AVTX
0 · Reply
MahiMe
MahiMe May. 5 at 8:40 PM
$HOTH Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients https://finance.yahoo.com/sectors/healthcare/articles/hoth-therapeutics-secures-european-authorization-201700125.html
1 · Reply
RaphaelRapoport
RaphaelRapoport May. 5 at 4:13 PM
$HOTH Whats next catalyst and where is CEO to promote this company?
1 · Reply